Sanofi’s Formulation Patents on Multibillion-Dollar Lantus® are Invalidated by U.S. Patent and Trademark Office via IPR, Announces Mylan

Mylan N.V. today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in its inter partes review (IPR) proceedings and found all claims of Sanofi’s Lantus (insulin glargine 100 Units/mL) formulation patents unp